BACKGROUND: Chronic seronegative hepatitis C virus (HCV) infection is defined as being HCV antibody (anti-HCV) negative, but HCV RNA positivity occurs in individuals infected with human immunodeficiency virus (HIV). However, associated factors are not well established because of the small number of reported cases. METHODS: Multivariate logistic regression analysis of HIV-infected subjects from 4 cohorts (Tien et al., 2006; Bonacini et al., 2001; George et al., 2002; and Hall et al., 2004) determined factors associated with HCV RNA positivity in anti-HCV-negative subjects. HCV enzyme immunoassay 2.0 was used to determine anti-HCV status. RESULTS: Among 1174 anti-HCV-negative, HIV-infected subjects, the prevalence of seronegative HCV infection was 3.2% (95% confidence interval [CI], 2.2%-4.3%). History of injection drug use (IDU; OR, 5.8; 95% CI, 2.7-12.8), higher alanine aminotransferase (ALT) level (OR, 2.0 per doubling; 95% CI, 1.3-3.2), and CD4 cell count <200 cells/ micro L (OR, 2.3; 95% CI, 1.1-4.8) were associated with HCV RNA positivity in anti-HCV-negative subjects. Among those with a history of IDU who had either a CD4 cell count <200 cells/ micro L or an ALT level greater than the upper limit of normal, the prevalence of seronegative HCV infection was 24% (95% CI, 13%-39%). CONCLUSIONS: Detectable HCV RNA in the context of a negative HCV enzyme immunoassay 2.0 result in HIV-infected patients is low, but higher than the reported prevalence in HIV-uninfected patients. Our findings suggest that HCV RNA testing should be performed in anti-HCV-negative, HIV-infected patients, especially those with a history of IDU and either a CD4 cell count <200 cells/ micro L or an abnormal ALT level.
BACKGROUND: Chronic seronegative hepatitis C virus (HCV) infection is defined as being HCV antibody (anti-HCV) negative, but HCV RNA positivity occurs in individuals infected with human immunodeficiency virus (HIV). However, associated factors are not well established because of the small number of reported cases. METHODS: Multivariate logistic regression analysis of HIV-infected subjects from 4 cohorts (Tien et al., 2006; Bonacini et al., 2001; George et al., 2002; and Hall et al., 2004) determined factors associated with HCV RNA positivity in anti-HCV-negative subjects. HCV enzyme immunoassay 2.0 was used to determine anti-HCV status. RESULTS: Among 1174 anti-HCV-negative, HIV-infected subjects, the prevalence of seronegative HCV infection was 3.2% (95% confidence interval [CI], 2.2%-4.3%). History of injection drug use (IDU; OR, 5.8; 95% CI, 2.7-12.8), higher alanine aminotransferase (ALT) level (OR, 2.0 per doubling; 95% CI, 1.3-3.2), and CD4 cell count <200 cells/ micro L (OR, 2.3; 95% CI, 1.1-4.8) were associated with HCV RNA positivity in anti-HCV-negative subjects. Among those with a history of IDU who had either a CD4 cell count <200 cells/ micro L or an ALT level greater than the upper limit of normal, the prevalence of seronegative HCV infection was 24% (95% CI, 13%-39%). CONCLUSIONS: Detectable HCV RNA in the context of a negative HCV enzyme immunoassay 2.0 result in HIV-infectedpatients is low, but higher than the reported prevalence in HIV-uninfectedpatients. Our findings suggest that HCV RNA testing should be performed in anti-HCV-negative, HIV-infectedpatients, especially those with a history of IDU and either a CD4 cell count <200 cells/ micro L or an abnormal ALT level.
Authors: Susan A Galel; D Michael Strong; Gary E Tegtmeier; Paul V Holland; Isamu K Kuramoto; Marti Kemper; Larry Pietrelli; James Gallarda Journal: Transfusion Date: 2002-11 Impact factor: 3.157
Authors: L Martín-Carbonero; V Soriano; E Valencia; J García-Samaniego; M López; J González-Lahoz Journal: AIDS Res Hum Retroviruses Date: 2001-11-01 Impact factor: 2.205
Authors: Susan L Stramer; Simone A Glynn; Steven H Kleinman; D Michael Strong; Sally Caglioti; David J Wright; Roger Y Dodd; Michael P Busch Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Inmaculada Castillo; Margarita Pardo; Javier Bartolomé; Nuria Ortiz-Movilla; Elena Rodríguez-Iñigo; Susana de Lucas; Clara Salas; Jose A Jiménez-Heffernan; Arturo Pérez-Mota; Javier Graus; Juan Manuel López-Alcorocho; Vicente Carreño Journal: J Infect Dis Date: 2003-12-31 Impact factor: 5.226
Authors: P Marcellin; M Martinot-Peignoux; A Elias; M Branger; F Courtois; R Level; S Erlinger; J P Benhamou Journal: J Infect Dis Date: 1994-08 Impact factor: 5.226
Authors: Sarah L George; Jenny Gebhardt; Donna Klinzman; Mathew B Foster; Kevin D Patrick; Warren N Schmidt; Beth Alden; Michael A Pfaller; Jack T Stapleton Journal: J Acquir Immune Defic Syndr Date: 2002-10-01 Impact factor: 3.731
Authors: Emma C Thomson; Eleni Nastouli; Janice Main; Peter Karayiannis; Joseph Eliahoo; David Muir; Myra O McClure Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch Journal: HIV Med Date: 2015-02-03 Impact factor: 3.180
Authors: Ajay R Bharti; Scott L Letendre; Tanya Wolfson; David Clifford; Ann C Collier; Benjamin Gelman; Justin McArthur; Christina Marra; Allen McCutchan; Susan Morgello; David Simpson; Ron J Ellis; Igor Grant Journal: J Clin Virol Date: 2011-09-15 Impact factor: 3.168
Authors: Judith Tsui; Eric Vittinghoff; Kathryn Anastos; Michael Augenbraun; Mary Young; Marek Nowicki; Mardge H Cohen; Marion G Peters; Elizabeth T Golub; Lynda Szczech Journal: Am J Kidney Dis Date: 2009-04-25 Impact factor: 8.860
Authors: Toni Frederick; Pamela Burian; Norah Terrault; Mardge Cohen; Michael Augenbraun; Mary Young; Eric Seaberg; Jessica Justman; Alexandra M Levine; Wendy J Mack; Andrea Kovacs Journal: AIDS Patient Care STDS Date: 2009-11 Impact factor: 5.078